LeMaitre Vascular, Inc. (NASDAQ:LMAT) CEO George W. Lemaitre sold 5,000 shares of the stock in a transaction dated Wednesday, August 23rd. The stock was sold at an average price of $33.91, for a total transaction of $169,550.00. Following the completion of the sale, the chief executive officer now directly owns 3,390,508 shares in the company, valued at approximately $114,972,126.28. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

LeMaitre Vascular, Inc. (NASDAQ LMAT) traded down 0.41% during trading on Friday, reaching $34.07. 174,565 shares of the company’s stock traded hands. The firm’s 50 day moving average is $31.97 and its 200-day moving average is $28.18. LeMaitre Vascular, Inc. has a 12 month low of $17.50 and a 12 month high of $36.09. The company has a market capitalization of $648.08 million, a price-to-earnings ratio of 48.67 and a beta of 0.65.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Thursday, July 27th. The medical instruments supplier reported $0.23 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.17 by $0.06. The company had revenue of $25.80 million during the quarter, compared to the consensus estimate of $25.42 million. LeMaitre Vascular had a return on equity of 15.02% and a net margin of 14.19%. The firm’s revenue was up 15.2% compared to the same quarter last year. During the same period last year, the company earned $0.14 earnings per share. Analysts expect that LeMaitre Vascular, Inc. will post $0.80 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 7th. Shareholders of record on Wednesday, August 23rd will be issued a $0.055 dividend. The ex-dividend date of this dividend is Monday, August 21st. This represents a $0.22 dividend on an annualized basis and a yield of 0.65%. LeMaitre Vascular’s payout ratio is currently 31.88%.

LeMaitre Vascular announced that its Board of Directors has authorized a share buyback program on Thursday, July 27th that allows the company to repurchase $7.50 million in shares. This repurchase authorization allows the medical instruments supplier to repurchase up to 1.4% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company’s board believes its stock is undervalued.

WARNING: This piece of content was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another website, it was stolen and reposted in violation of United States and international copyright & trademark laws. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/08/26/lemaitre-vascular-inc-lmat-ceo-george-w-lemaitre-sells-5000-shares.html.

A number of analysts recently weighed in on LMAT shares. Stifel Nicolaus increased their price objective on shares of LeMaitre Vascular from $25.00 to $29.00 and gave the stock a “buy” rating in a report on Friday, April 28th. Zacks Investment Research raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating and set a $36.00 price objective on the stock in a report on Friday, April 28th. Craig Hallum started coverage on shares of LeMaitre Vascular in a report on Tuesday, June 6th. They issued a “hold” rating and a $31.00 price objective on the stock. Benchmark Co. cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Monday, July 10th. They noted that the move was a valuation call. Finally, Canaccord Genuity cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating and set a $28.00 price objective on the stock. in a report on Monday, July 10th. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $30.17.

A number of large investors have recently modified their holdings of LMAT. Blair William & Co. IL increased its stake in shares of LeMaitre Vascular by 6.9% in the first quarter. Blair William & Co. IL now owns 11,977 shares of the medical instruments supplier’s stock worth $295,000 after buying an additional 768 shares during the last quarter. SG Americas Securities LLC acquired a new stake in shares of LeMaitre Vascular during the first quarter worth $353,000. Prudential Financial Inc. increased its stake in shares of LeMaitre Vascular by 2.1% in the first quarter. Prudential Financial Inc. now owns 97,350 shares of the medical instruments supplier’s stock worth $2,398,000 after buying an additional 2,040 shares during the last quarter. Congress Asset Management Co. MA acquired a new stake in shares of LeMaitre Vascular during the first quarter worth $751,000. Finally, Oxford Asset Management acquired a new stake in shares of LeMaitre Vascular during the first quarter worth $359,000. Institutional investors and hedge funds own 67.12% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.

Insider Buying and Selling by Quarter for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Stock Ratings for LeMaitre Vascular Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular Inc. and related stocks with our FREE daily email newsletter.